Use of PSA measurement in practice.
(CPG) series provides an overview of one CPG each month. The overview includes a brief summary of the guideline's content, as well as the identification of some factors by which the author has critiqued it. The first article in the series reviewed the steps of CPG critique. Subsequent columns have described CPGs related to viral upper respiratory illnesses, tobacco dependence, menopause and perimenopause, and musculoskeletal evaluation. This month, the column describes a CPG titled: Prostate-Specific Antigen (PSA) Best Practice Policy, from the American Urological Association (AUA). As prostate cancer is the leading cause of cancer deaths among U.S. men, this set of recommendations should have wide application.
Goolsby
M J
MJ
University Health Care System, Augusta, Georgia, USA. mgoolsby@uh.org
D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008403:Mass Screening; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000451:nursing
D017430:Prostate-Specific Antigen